Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
Jason Grebely(UNSW Sydney), Heather Platt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ernest Asante‐Appiah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ronald Nahass, Oren Shibolet(Tel Aviv University), David Iser(The Alfred Hospital), Gregory J. Dore(UNSW Sydney), Frederick L. Altice(Heidelberg University), Peggy Hwang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Olav Dalgård(University of Oslo), Cheng‐Yuan Peng(China Medical University), Alain H. Litwin(Prisma Health), Barbara Haber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anne F. Luetkemeyer(University of California, San Francisco), Edward Gane(University of Auckland), Michelle M. Kelly(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eliav Barr(University of New Mexico), Brian Conway, Isaias Noel Gendrano(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brianna L. Norton(Albert Einstein College of Medicine)
Cited by 20
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
|Unknown|2006|940
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728